U.S Anticonvulsant Medications: Label and Off-Label Uses
U.S Anticonvulsant Medications: Label and Off-Label Uses
RELEASE DATE
30-Aug-2001
30-Aug-2001
REGION
North America
North America
Research Code: A062-01-00-00-00
SKU: HC00790-NA-MR_04459
$2,450.00
In stock
SKU
HC00790-NA-MR_04459
Description
This market study focuses on the U.S. Anticonvulsant Market: Label and Off-label Uses. Information is presented on specific CNS disorders (epilepsy, bipolar, migraine and pain), the current role of anticonvulsants in therapy and the potential future role. Forecasted anticonvulsant revenues are presented for the 2001 to 2005 period.
Table of Contents
Executive Summary
- Executive Summary
Introduction
- Introduction To The U.S. Anticonvulsant Market
- Study Objectives
Methodology
- Primary And Secondary Research
- Frost And Sullivan's Market Forecasting Model
Introduction
U.S. Anticonvulsant Market Performance: 1990 to 2000
- FDA-Approved First-Generation Anticonvulsants
- FDA-Approved Second-Generation Anticonvulsants: 1993 - 1996
- FDA-Approved Second-Generation Anticonvulsants: 1997 - 2000
- Alternative Therapies
Market Engineering Awards
- U.S. Anticonvulsant Market Revenues: 1990 - 2000
- Second-Generation Anticonvulsant Market Performance: 1997 - 2000
- Market Engineering Analysis
Disease Overview
Diagnosing And Treating Epilepsy
Epilepsy Market Share Analysis (2000)
Major Opportunities And Challenges
- Introduction
- Clinical Presentation
Forecasts and Trends
- Diagnosis and Seizure Classification
- Tolerability
- Age And Medical Condition
- Health Care Coverage
- Epilepsy Market Potential For Second-Generation Anticonvulsants
Strategic Recommendations
- First-Generation Anticonvulsants
- Second-Generation Anticonvulsants
Disease Overview
Diagnosing And Treating Bipolar Disorder
Bipolar Market Share Analysis (2000)
Major Opportunities and Challenges
Forecast And Trends
Strategic Recommendations
Pain Markets
Migraine Prophalaxis Markets
Popular Topics
This market study focuses on the U.S. Anticonvulsant Market: Label and Off-label Uses. Information is presented on specific CNS disorders (epilepsy, bipolar, migraine and pain), the current role of anticonvulsants in therapy and the potential future role. Forecasted anticonvulsant revenues are presented for the 2001 to 2005 period.
No Index | Yes |
---|---|
Podcast | No |
Industries | Healthcare |
WIP Number | A062-01-00-00-00 |
Is Prebook | No |